Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02398240 · ClinicalTrials.gov registry record · Phase 2
Brentuximab for Newly Diagnosed Hodgkin Disease
A Phase 2 study of Hodgkin Lymphoma, sponsored by Mitchell Cairo.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02398240 is a Phase 2 study of Hodgkin Lymphoma that has completed, run by Mitchell Cairo. The registered enrollment target is 40 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02398240, a Phase 2 study of Hodgkin Lymphoma, has completed, sponsored by Mitchell Cairo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Vincristine
- DRUG Brentuximab Vedotin
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-05 |
| Est. Completion | 2022-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02398240
The ClinicalTrials.gov registry entry for NCT02398240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (76% lower). The listed sponsor is Mitchell Cairo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Doxorubicin is the first listed.
NCT02398240 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02398240 about?
NCT02398240 is a clinical study titled "Brentuximab for Newly Diagnosed Hodgkin Disease". The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
What is the current status of trial NCT02398240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-05. Estimated completion is 2022-12.
What conditions does trial NCT02398240 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT02398240?
The interventions under investigation include: Doxorubicin (DRUG), Rituximab (DRUG), Vincristine (DRUG), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT02398240?
This trial is sponsored by Mitchell Cairo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02398240 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.